BIOLUMPI VAXIN
- Biolumpi Vaxin, developed by Bharat Biotech in collaboration with the Indian Council for Agricultural Research (ICAR), is the world’s first vaccine for Lumpy Skin Disease (LSD) in cattle and buffaloes.
- It was developed by Biovet, a group company of Bharat Biotech.
- Recently, it has received approval from the Central Drug Standards Control Organization (CDSCO), marking a significant advancement in veterinary healthcare in India.
KEY FEATURES
- Global First:
- Biolumpi Vaxin is the first-ever DIVA (Differentiating Infected from Vaccinated Animals) marker vaccine for Lumpy Skin Disease.
- It represents a significant milestone in global veterinary medicine.
- DIVA Technology:
- DIVA technology allows differentiation between infected and vaccinated animals.
- This helps in effective disease surveillance and control programs, ensuring that only infected animals are isolated while vaccinated ones can continue to move freely.
- High Safety and Efficacy:
- The vaccine has been rigorously tested for quality, safety, and effectiveness to ensure its suitability for use in cattle and buffaloes.
- Single-Dose Regimen:
- It is administered as a single dose per year to cattle and buffaloes aged above 3 months.
- Vaccine Strain:
- The vaccine is developed using the Lumpy Skin Disease Virus/Ranchi/2019 strain sourced from ICAR-NRCE, Hisar.
BACKGROUND OF LUMPY SKIN DISEASE
- Lumpy Skin Disease (LSD) is a viral infection affecting cattle and buffaloes, primarily causing severe economic losses in the dairy and livestock industry.
- Cause: The disease is caused by the Lumpy Skin Disease Virus (LSDV), which belongs to the Poxviridae family.
- Spread: The virus spreads through blood-sucking vectors like ticks, mites, houseflies, and mosquitoes. It can also be transmitted through contaminated water, fodder, and feed.
- Symptoms:
- Visible lumps or nodules on the skin.
- Fever, swelling, and lesions.
- Economic Impact:
- Reduced milk production.
- Infertility in livestock.
- Increased mortality in some cases, leading to severe economic losses.
WHAT IS DIVA?
- What is DIVA Technology?
- DIVA vaccines are designed to differentiate between animals that have been naturally infected and those that have been vaccinated.
- This differentiation helps in preventing disease outbreaks while enabling efficient disease surveillance and eradication.
- Advantages of DIVA Vaccines:
- Identification of Infected Animals: Infected animals can be easily identified, and restrictions can be imposed only on them, while vaccinated animals are allowed to move freely.
- Monitoring Vaccine Efficacy: DIVA vaccines allow monitoring of wild-type virus transmission in vaccinated populations, ensuring the vaccine’s effectiveness.
- Disadvantages of DIVA Vaccines:
- Less Effectiveness: DIVA vaccines may not be as effective as traditional vaccines, potentially leading to incomplete protection.
- Special Diagnostic Tests: Special tests are required to distinguish between infected and vaccinated animals. These tests may not be as sensitive or quick as conventional tests.
- Complex Development: Developing DIVA vaccines is a challenging process due to the need for precise technology and techniques to differentiate infections.
Note: Connect with Vajirao & Reddy Institute to keep yourself updated with latest UPSC Current Affairs in English.
Note: We upload Current Affairs Except Sunday.